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013.01.00Abstract Aim of the work: This study aimed to assess serum levels of some adipocytokines (leptin,
adiponectin and resistin) and IL-6 in patients with ankylosing spondylitis (AS) to evaluate their
relationship to disease activity and functional capacity.
Patient and method: Twenty-ﬁve AS patients were enrolled. Body mass index (BMI), Bath AS
Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI) and acute phase reactants,
such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, were assessed.
Serum leptin, adiponectin, resistin and interleukin (IL)-6 levels were determined using enzyme-
linked immunosorbent assay (ELISA).
Results: The mean levels of leptin (9.1 ± 3.9 ng/ml), resistin (2.27 ± 1.15 ng/ml) and IL-6
(9.2 ± 5.8 pg/ml); were signiﬁcantly elevated in patients with AS compared to the controls
(p= 0.000, p= 0.0028 and p= 0.000, respectively). Only serum leptin levels correlated signiﬁ-
cantly with IL-6 (p= 0.004), and both serum leptin and IL-6 levels correlated signiﬁcantly with
BASDAI (p= 0.02 and p= 0.005, respectively), ESR (p= 0.04) and CRP (p= 0.01 and
p= 0.006, respectively) in AS patients. Serum resistin did not correlate with any of the AS disease
parameters, whereas, serum adiponectin neither signiﬁcantly elevated nor correlated with any of
these parameters.artment of Rheumatology &
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66 G.G. Elolemy et al.Conclusion: The associations of signiﬁcantly increased levels of serum leptin and IL-6 with AS
disease activity parameters give clues to their role in the inﬂammatory process of the disease. Failure
to ﬁnd any correlation between high serum resistin levels and AS disease activity parameters is sug-
gestive of its role in the pathogenesis rather than disease activity.
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Open access under CC BY-NC-ND license.1. IntroductionWhite adipose tissue is an emerging active participant in regu-
lating physiologic and pathologic processes, including immu-
nity and inﬂammation [1,2].
Adipose tissue produces a variety of pro-inﬂammatory and
anti-inﬂammatory factors, including the adipocytokines leptin,
adiponectin, resistin, and visfatin, as well as cytokines and che-
mokines, such as tumor necrosis factor-a (TNF-a), interleukin
(IL)-6, and others [3].
The inﬂuence of these adipocytokines on immunity and
inﬂammation has been well documented [4]. Leptin has sys-
temic effects apart from those related to energy homeostasis,
including regulation of neuroendocrine, reproductive, hemato-
poietic and immune function [5].
It is generally accepted that leptin displays pro-inﬂamma-
tory effects, while adiponectin is considered to primarily act
as an anti-inﬂammatory molecule [6]. It has been reported that
leptin receptors are expressed on B and T-cells. Leptin may
stimulate T cell proliferation, promote a Th1 response, inﬂu-
ence T-cell activation, and activate macrophages and mono-
cytes, thereby enhancing their phagocytic activities [7].
Adiponectin exerts a variety of anti-inﬂammatory activities,
interfering with the macrophage function by inhibiting phago-
cytosis, IL-6 or TNF-a production, reducing T-cell function,
and promoting the release of IL-10 and IL-1 receptor antago-
nist [8].
Resistin is an adipocytokine initially described as a poly-
peptide produced by adipose tissue. It is regulated by peroxi-
some proliferator-activated receptor gamma providing a link
between obesity and insulin resistance [9]. Later, it has been
identiﬁed that while resistin levels were very low in human adi-
pocytes, its level was higher in mononuclear leukocytes, mac-
rophages, spleen, and bone marrow cells [10]. Thus, it was
suggested that resistin levels had a better relationship with sub-
clinical inﬂammation than with insulin resistance [11].
Ankylosing spondylitis (AS) is a chronic inﬂammatory
disease that primarily affects the sacroiliac joints and spine;
some patients may also have extra-articular manifestations
[12,13].
It is suspected that upregulation of pro-inﬂammatory cyto-
kines is effective in the immunopathogenesis of AS. It is found
that TNF-a and IL-6 levels are higher in AS patients than in
healthy people [14] with some of them showing good correla-
tion with the parameters reﬂecting disease activity [15].
Leptin increases the production of TNF-a, which sup-
presses the transcription of adiponectin in adipocytes, and
treatment of cultured macrophages with adiponectin markedly
inhibits their phagocytic activity and production of TNF-a in
response to stimulation with lipopolysaccharide [6,16]. Few
studies have evaluated serum levels of leptin and adiponectin
in AS. The aim of this study was to assess serum levels ofleptin, adiponectin, resistin, and IL-6 in patients with AS to
evaluate their relationship to disease activity and functional
capacity.
2. Patients and methods
2.1. Patients
Twenty-ﬁve patients with deﬁnite AS (23 males and 2 females),
diagnosed according to the modiﬁed New York criteria of AS
[17] were selected from the attendants of the rheumatology
and rehabilitation clinic at Benha University Hospitals. Six pa-
tients (24%) were onmethotrexate andNSAIDs therapy and 15
(60%) were receiving NSAID and sulfasalazine. Three patients
(12%) were receiving only NSAIDs. Two patients were on no
medication. Twenty (18 males and 2 females) sex, age and body
mass index-matched healthy subjects were recruited as controls.
The research protocol was approved by the Ethics Commit-
tee of our institution and informed written consents were ob-
tained from all participants. We excluded patients with
diabetes mellitus, other endocrine disorders, chronic liver dis-
ease, chronic renal disease, recent history of glucocorticoids in-
take and postmenopausal status.
2.2. Clinical and physical measurement
Patients were clinically evaluated, the axial as well as the
peripheral joints were assessed. Lumbar schober, occiput-wall
distance and chest expansion were measured as part of the clin-
ical assessment. Patients were evaluated using the Bath AS dis-
ease activity index (BASDAI) [18] and Bath AS Functional
Index (BASFI) [19]. Waist circumference (cm) and BMI calcu-
lated as weight/height2 (kg/m2) were obtained.
2.3. Biochemical assessments
Venous blood samples were obtained after overnight fasting at
the same time of physical assessment from all patients and
controls.
The following assessments were done:
- A citrated blood sample was used for the assay of erythro-
cyte sedimentation rates (ESR) by the modiﬁed Westergren
method.
- Serum was separated from another plain (no additive) tube
for measurement of C-reactive protein (CRP) levels by
immunonephelometry using Turbox plus instrument.
- Serum concentrations of fasting glucose, total cholesterol
and triglycerides were determined by Cobas Integra A
400 clinical chemistry analyzer (Roche).
- High-density lipoprotein cholesterol (HDL-C) was deter-
mined by kits supplied from Sigma diagnostics.
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lated using the Friedewald formula [20].
- An aliquot of serum was stored at 20 C until other inves-
tigations are assayed.
- Serum leptin and adiponectin were measured by speciﬁc
ELISA assay using material and protocols supplied by
the provider Biovendor (Heidelberg, Germany).
- Serum resistin and IL-6 were determined by ELISA assay
by kit supplied from Abcam (Cambridge, UK).
2.4. Radiological examination
Plain radiographic examination was performed for the pelvis
and entire spine for all patients as a part of assessment of
AS, in addition to plain X-ray for any affected joints.
Statistical analysis was performed using Statistical Package
for Social Sciences software (SPSS), version 13.0. Quantitative
variables (demographic, clinical and laboratory) were pre-
sented as the mean ± SD. Student’s (t) test was used to com-
pare means. Relationships between parameters were analyzed
using Pearson correlation coefﬁcients (r). P value less than
0.05 was considered signiﬁcant.3. Results
- Patient characteristics are represented in (Table 1): The
mean disease duration was 45.2 ± 11.2 months, all patients
(100%) had axial articular involvement, 6 patients (24%)Table 1 Demographic, clinical and laboratory characteristics of stu
Parameters Groups
AS patients (no = 25)
Age (years) 29.11 ± 7.86
Disease duration (months) 45.2 ± 11.2
Anthropometric measurements
BMI (kg/m2) 25.07 ± 3.04
Waist (cm) 78.29 ± 8.2
Articular manifestations
Axial 25 (100%)
Peripheral 6 (24%)
Extraarticular manifestations
Uveitis 8 (32%)
Cardiac 1 (4%)
BASDAI 5.1 ± 1.7
BASFI 5.6 ± 1.9
Lipid proﬁle
Total cholesterol (mg/dl) 151.22 ± 7.7
HDL cholesterol (mg/dl) 54.23 ± 3.7
LDL cholesterol (mg/dl) 77.34 ± 5.12
TG (mg/dl) 82.14 ± 7.2
ESR (mm/1st h) 29.2 ± 9.1*
CRP (mg/l) 15.4 ± 4.8*
AS, ankylosing spondylitis; BMI, body mass index; BASDAI, bath ank
spondylitis functional index; HDL, high-density lipoprotein cholesterol;
erythrocyte sedimentation rate; CRP, C-reactive protein.
* Signiﬁcantly different.had peripheral articular manifestations, 8 patients (32%)
had uveitis while, only one patient (4%) had cardiac
involvement in the form of aortic regurgitation. The mean
value of lumbar ﬂexion was 3.08 ± 2.19 and the mean
value of occiput-wall distance (cm) was 4.6 ± 3.5. Chest
expansion (cm) value was determined as 3.5 ± 1.5.
- The mean BASDAI was 5.1 ± 1.7 and the mean BASFI
was 5.6 ± 1.9. As regards inﬂammatory markers, both
ESR and CRP were signiﬁcantly higher in patients
(29.2 ± 9.1 mm/h) and (15.4 ± 4.8 mg/l) than controls
(13.4 ± 2.1 mm/h) and (5.9 ± 2.2 mg/l), respectively.
- There was a statistical signiﬁcant increase in serum leptin
(p= 0.000), resistin (p= 0.0028) and IL-6 (p= 0.000)
levels in patients than in controls, while, there was an insig-
niﬁcant difference in adiponectin serum levels between
patients and controls (p= 0.19) (Table 2). AS patients
with peripheral articular manifestations had signiﬁcantly
higher serum leptin (10.9 ± 1.9 ng/ml) and IL-6
(11.8 ± 1.01 pg/ml) levels compared to those without
peripheral involvement (7.6 ± 3.3 ng/ml and 8.1 ± 4.2 pg/
ml respectively), where p= 0.03 and p= 0.046, respec-
tively (Fig. 1).
- Signiﬁcant correlations of serum leptin levels with anthro-
pometric measurements (p= 0.007 and p= 0.01 for BMI
and waist, respectively), BASDAI (p= 0.02), ESR
(p= 0.04), CRP (p= 0.01) and IL-6 (p= 0.004) but not
with BASFI (p= 0.19) were found. Whereas, there were
signiﬁcant correlations of serum IL-6 levels with BASDAI
(p= 0.005), BASFI (p= 0.01), ESR (p= 0.04) and CRP
(p= 0.006) but not with anthropometric measurementsdied groups.
Control group (no = 20) t p
32.12 ± 6.41 1.42 0.17
– – –
26.22 ± 2.66 1.35 0.19
79.3 ± 7.1 1.06 0.29
– – –
– – –
– – –
– – –
154.41 ± 8.9 1.32 0.2
51.5 ± 9.2 1.25 0.18
79.4 ± 7.4 1.07 0.28
84.33 ± 9.7 0.84 0.39
13.4 ± 2.1 8.4 0.000
5.9 ± 2.2 8.1 0.000
ylosing spondylitis disease activity index; BASFI, bath ankylosing
LDL, low-density lipoprotein cholesterol; TG, triglycerides; ESR,
Table 2 Adipocytokines and IL-6 serum levels in AS patients and control.
Parameters Groups
AS patients (no = 25) Control group (no = 20) t p
Leptin (ng/ml) 9.1 ± 3.9* 4.3 ± 3.5 4.36 0.000
Adiponectin (ug/ml) 10.44 ± 0.63 10.21 ± 0.52 1.35 0.19
Resistin (ng/ml) 2.27 ± 1.15* 1.42 ± 0.36 4.11 0.0028
IL-6 (pg/ml) 9.2 ± 5.8* 2.3 ± 1.9 5.57 0.000
IL-6, interleukin-6.
* Signiﬁcantly different.
Figure 1 Serum adipocytokines and IL-6 levels in AS patients
with and without peripheral articular involvement.
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Consistently, we did not ﬁnd any correlations of either
adiponectin or resistin serum levels with any of the disease
related variables (p> 0.05) (Table 3).
4. Discussion
This study aimed to assess levels of leptin, adiponectin, resistin
and IL-6 in patients with AS to evaluate their relationship to
disease activity and functional capacity.
The results of our study demonstrated that serum levels of
leptin, resistin and IL-6 were signiﬁcantly increased in AS pa-
tients compared to healthy controls. Serum leptin levels also
signiﬁcantly correlated with anthropometric measurements,
BASDAI, BASFI, ESR, CRP and IL-6.
Increased serum levels of different pro-inﬂammatory cyto-
kines in AS patients have been reported with good correlation
with the disease activity parameters [15,21].
Many different tissues secrete IL-6 [22], including adipose
tissue [23] and its pivotal role in the pathogenesis of AS has
been suggested. Elevated levels of IL-6 and TNF-a have been
found in the sera of AS patients in a study done by Gratacos
et al. [21], verifying good correlation between IL-6 and disease
activity.
Our results were in agreement with those of Park et al. [24],
who found that patients with AS had signiﬁcantly elevated ser-
um levels of IL-6 correlating signiﬁcantly with disease activity
(BASDAI) and CRP while non signiﬁcantly correlated with
ESR.
The signiﬁcantly higher leptin levels in our study could be
explained by the results obtained by Park et al. [25], whodemonstrated increased expression of leptin, IL-6 and TNF-
a mRNA in peripheral blood mononuclear cells (PBMCs)
from patients with AS and reported that stimulation of
PBMCs with leptin signiﬁcantly induced dose-dependent in-
creases of IL-6 and TNF-a production in PBMCs suggesting
a role of leptin in the pathogenesis of the disease.
Contrarily, Derdemezis et al. [26], observed no difference in
leptin levels between controls andAS patients and found no cor-
relation with any disease parameters. In addition, Sari et al. [27],
observed that leptin levels were signiﬁcantly lower inASpatients
than in controls and reported a signiﬁcant correlation with CRP
supporting the theory that chronic inﬂammation reduces the
body fat content and lower leptin production by adipocytes,
as adipose tissue is the main source of serum leptin.
This incongruity could be explained by differences in some
related factors, such as gender, menopausal status, BMI and
medications which can potentially alter leptin levels and dis-
ease activity of AS.
Trujillo and his colleagues [28], demonstrated that in-
creased local IL-6 concentration can increase leptin production
in human adipose tissue. Baumann et al. [29], supported the
role of leptin in inﬂammatory responses by signaling capabili-
ties of leptin receptor on IL-6-type cytokine receptors.
Moreover, Tartaglia et al. [30], reported sequence homol-
ogy between leptin receptor and members of the class I cyto-
kine receptor superfamily, including the receptor for IL-6.
Furthermore, for AS patients with peripheral articular
manifestations, Leptin and IL-6 serum levels were signiﬁcantly
higher than those of patients with only axial involvement.
Concordant to our results, Huang et al. [31], observed a sig-
niﬁcant increase of IL-6 serum levels in AS female patients
with syndesmophytes .
In this study, we found insigniﬁcant differences (p= 0.19)
between patients and controls as regards adiponectin serum
levels as well as no correlations with any of the disease related
parameters.
Our results are in accordance with those of Toussirot et al.
[32], who found normal adiponectin serum levels in their AS pa-
tients but failed to ﬁnd any correlation between circulating
adiponectin and BMI, ESR, CRP or BASDAI in those patients.
In the same context, Fantuzzi [8], reported that pro-inﬂamma-
tory cytokines including (TNF-a, IL-6) inhibit the production of
adiponectin that explains the inverse correlation between adipo-
nectin levels and inﬂammatory markers found in his study. Also,
Fernandez-Real and his associates [33] suggested that adiponectin
is related to the inﬂammatory process by inducing the release of
IL-10 and IL-1 receptor antagonist.
Derdemezis et al. [34], found elevated adiponectin levels,
not correlated with any disease parameter in AS patients.
Table 3 Correlations of adipocytokines and IL-6 serum levels with clinical and laboratory parameters in AS patients.
Parameter Protein
Leptin (ng/ml) Adiponectin (ug/ml) Resistin (ng/ml) IL-6 (pg/ml)
r p r p r p r p
Anthropometric measurements
BMI (kg/m2) 0.52 0.007* 0.28 0.16 0.25 0.17 0.15 0.31
Waist (cm) 0.48 0.01* 0.21 0.19 0.26 0.17 0.12 0.33
BASDAI 0.45 0.02* 0.17 0.29 0.27 0.16 0.58 0.005*
BASFI 0.21 0.19 0.09 0.8 0.24 0.16 0.49 0.01*
ESR (mm/1st h) 0.4 0.04* 0.42 0.16 0.24 0.16 0.4 0.04*
CRP (mg/l) 0.48 0.01* 0.26 0.17 0.15 0.31 0.55 0.006*
IL-6 (pg/ml) 0.61 0.004* 0.29 0.26 0.28 0.26
BMI, body mass index; BASDAI, bath ankylosing spondylitis disease activity index; BASFI, bath ankylosing spondylitis functional index; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, interleukin-6.
* Signiﬁcantly different.
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done on RA patients [34–36] and SLE patients [37–39]. These
paradoxical results were based on the fact that under certain
circumstances adiponectin seems to induce the expression of
TNF-a [40], contradicting its anti-inﬂammatory role and ren-
dering a question regarding its exact action.
Our AS patients exhibited a signiﬁcant elevation in serum
resistin levels, however we failed to ﬁnd any correlation be-
tween its levels and disease related parameters.
Patel et al. [10], reported that resistin mRNA is detectable
in circulating mononuclear cells suggesting the role of human
resistin in the inﬂammatory process.
Our results are consistent with those ofKocabas et al. [41], who
found that the serum resistin levels were signiﬁcantly increased in
patientswithAS compared to healthy people, but did not correlate
with activity markers including ESR, CRP and BASDAI.
In conclusion, adipocytokines have different roles in
inﬂammatory sequences occurring in AS. Leptin, together with
IL-6, correlated well with disease activity parameters giving
clues to their pro-inﬂammatory role in the disease.
Failure to ﬁnd any correlation between high serum resistin
levels and AS disease activity parameters is suggestive of its
role in the pathogenesis rather than disease activity. Adiponec-
tin is only a bystander in AS and its role in this disease process
is yet to be clariﬁed.
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